Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Sarepta Therapeutics' Stock Is Surging Higher Today

By George Budwell - May 25, 2016 at 11:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA isn't quite ready to issue a final decision on Sarepta's controversial Duchenne muscular dystrophy drug.

What: Shares of Sarepta Therapeutics (SRPT 1.00%) rose by as much as 26% immediately after the opening bell today on the news that the FDA will need additional time to issue its final decision on the biotech's experimental Duchenne muscular dystrophy (DMD) drug, eteplirsen. The agency was scheduled to release its final verdict on the hotly contested drug by tomorrow.

So what: The market is apparently taking this delay as a sign that the FDA may greenlight the drug, despite the agency's serious doubts about its effectiveness.

Now what: Per Sarepta's press release, the FDA didn't earmark a new target review date. Rather, the agency only mentioned that it plans to complete the review in "as timely a manner as possible." Reading between the lines here, I think the FDA is likely very close to issuing a final decision, and perhaps only needed an extra couple of days to wrap up its review.

That said, I don't think this delay is necessarily a positive sign indicating that a conditional approval is forthcoming. After all, the FDA also extended its review of BioMarin Pharmaceutical's rival DMD drug, but ultimately rejected drisapersen's regulatory application. Moreover, the agency basically gutted eteplirsen's clinical program in its internal review, and the FDA's external panel of experts didn't exactly offer much in the way of a counterargument. In short, the most likely outcome remains a Complete Response Letter.   

As the FDA could surprise the Street either way, though, I'm perfectly content to watch this looming binary event from the safety of the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$75.71 (1.00%) $0.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.